Metformin-Loaded Hydrogel Shows Promise for Age-Related Bone Healing

As populations age globally, bone fractures and defects in elderly patients have become increasingly difficult to treat due to declining repair capacity. The primary culprit is the aging of bone marrow mesenchymal stem cells (BMSCs), which lose their ability to proliferate and differentiate effectively, while chronic inflammation and oxidative stress create a hostile healing environment.

Researchers developed an innovative solution: a metformin-loaded composite hydrogel (MCTM) that addresses multiple aging-related barriers simultaneously. The system combines carboxymethyl chitosan, tannic acid, and manganese ions with metformin to create a multifunctional drug delivery platform.

Laboratory testing revealed that manganese significantly improved the hydrogel's mechanical properties and controlled drug release, ensuring sustained metformin delivery at repair sites. Both cell culture and animal studies demonstrated excellent biocompatibility and the system's ability to rejuvenate aging stem cells while improving the local tissue environment.

The hydrogel showed promise for overcoming the complex challenges of bone repair in elderly patients by simultaneously targeting stem cell senescence, inflammation, oxidative stress, and infection risk. This multifaceted approach represents a significant advance over current treatments that typically address only single aspects of age-related bone healing problems, potentially offering new hope for improving outcomes in an aging population.